Active Biotech Interim Report January - March 2020

April 23, 2020 08:30 (CEST)Regulatory

First quarter in brief

  • Active Biotech announces new direction
  • Patent regarding use of tasquinimod in the treatment of multiple myeloma granted in Japan

Events after the end of the period

  • Due to the current situation with the COVID-19 pandemic the Investment day planned to be held in connection with the Annual general meeting will be postponed to a later timepoint

Financial summary

SEK MJan-MarFull-year
 20202019 2019
Net sales0.55.5 8.4
Operating loss-9.7-6.4 -32.3
Loss after tax-10.1-8.1 -34.1
Loss per share (SEK)-0.07-0.06 -0.24
Cash and cash equivalents (at close of the period)47.916.4 59.7

For further information, please contact:

  Helén Tuvesson, CEO
  Tel: +46 (0)46-19 21 56


  Hans Kolam, CFO
  Tel: +46 (0)46 19 20 44

Active Biotech AB
(Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 (0)46-19 20 00


The report is also available at

Active Biotech is obligated to make public the information contained in this report pursuant to the EU Market Abuse Regulation. This information was provided to the media, through the agency of the contact person set out above, for publication on April 23, 2020, at 08.30 a.m. CET. 


Active Biotech Interim Report January - March 2020